These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37990163)

  • 1. Adjunctive tonic motor activation enables opioid reduction for refractory restless legs syndrome: a prospective, open-label, single-arm clinical trial.
    Buchfuhrer MJ; Roy A; Rodriguez S; Charlesworth JD
    BMC Neurol; 2023 Nov; 23(1):415. PubMed ID: 37990163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tonic motor activation (TOMAC) for medication-refractory restless legs syndrome: a randomized clinical trial.
    Bogan RK; Roy A; Kram J; Ojile J; Rosenberg R; Hudson JD; Scheuller HS; Winkelman JW; Charlesworth JD
    Sleep; 2023 Oct; 46(10):. PubMed ID: 37458698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of tonic motor activation for treatment of medication-refractory restless legs syndrome: A 24-Week Open-Label Extension Study.
    Roy A; Ojile J; Kram J; Olin J; Rosenberg R; Hudson JD; Bogan RK; Charlesworth JD
    Sleep; 2023 Oct; 46(10):. PubMed ID: 37439365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Safety, Dose Stability, and Efficacy of Opioids for Patients With Restless Legs Syndrome in the National RLS Opioid Registry.
    Winkelman JW; Wipper B; Zackon J
    Neurology; 2023 Apr; 100(14):e1520-e1528. PubMed ID: 36697248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline and 1-year longitudinal data from the National Restless Legs Syndrome Opioid Registry.
    Winkelman JW; Purks J; Wipper B
    Sleep; 2021 Feb; 44(2):. PubMed ID: 32918469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
    Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
    Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pain, opioids, and sleep: implications for restless legs syndrome treatment.
    Trenkwalder C; Zieglgänsberger W; Ahmedzai SH; Högl B
    Sleep Med; 2017 Mar; 31():78-85. PubMed ID: 27964861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Pressure on Abductor Hallucis and Flexor Hallucis Brevis Muscles to Manage Moderate to Severe Primary Restless Legs Syndrome.
    Kuhn PJ; Olson DJ; Sullivan JP
    J Am Osteopath Assoc; 2016 Jul; 116(7):440-50. PubMed ID: 27367949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of restless legs syndrome during opioid discontinuation.
    McCarter SJ; Labott JR; Mazumder MK; Gebhard J; Cunningham JL; Loukianova LL; Gilliam WP; Lipford MC
    J Clin Sleep Med; 2023 Apr; 19(4):741-748. PubMed ID: 36692170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioids for restless legs syndrome.
    de Oliveira CO; Carvalho LB; Carlos K; Conti C; de Oliveira MM; Prado LB; Prado GF
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD006941. PubMed ID: 27355187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How effective are treatment guidelines for augmented RLS?
    Yeung Laiwah J; Winkelman JW
    Sleep; 2022 Jul; 45(7):. PubMed ID: 35532181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire.
    Allen R; Oertel W; Walters A; Benes H; Schollmayer E; Grieger F; Moran K; Kohnen R
    Sleep Med; 2013 Dec; 14(12):1375-80. PubMed ID: 24246378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Utility of Opioids for Restless Legs Syndrome.
    Mackie SE; Winkelman JW
    Drugs; 2017 Aug; 77(12):1337-1344. PubMed ID: 28616844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
    Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R;
    Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral high-frequency noninvasive peroneal nerve stimulation evokes tonic leg muscle activation for sleep-compatible reduction of restless legs syndrome symptoms.
    Charlesworth JD; Adlou B; Singh H; Buchfuhrer MJ
    J Clin Sleep Med; 2023 Jul; 19(7):1199-1209. PubMed ID: 36856064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive neuromodulation reduces symptoms of restless legs syndrome.
    Buchfuhrer MJ; Baker FC; Singh H; Kolotovska V; Adlou B; Anand H; de Zambotti M; Ismail M; Raghunathan S; Charlesworth JD
    J Clin Sleep Med; 2021 Aug; 17(8):1685-1694. PubMed ID: 33949942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron for the treatment of restless legs syndrome.
    Trotti LM; Becker LA
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD007834. PubMed ID: 30609006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.
    Trenkwalder C; Canelo M; Lang M; Schroeder H; Kelling D; Berkels R; Schollmayer E; Heidbrede T; Benes H
    Sleep Med; 2017 Feb; 30():257-265. PubMed ID: 26896370
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.